Oncotarget

Meta-Analysis:

Prognostic role of TET2 deficiency in myelodysplastic syndromes: A meta-analysis

Yun Lin, Zhijuan Lin, Kun Cheng, Zhihong Fang, Zhifeng Li, Yiming Luo _ and Bing Xu

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:43295-43305. https://doi.org/10.18632/oncotarget.17177

Metrics: PDF 1580 views  |   HTML 1679 views  |   ?  


Abstract

Yun Lin1, Zhijuan Lin1, Kun Cheng2, Zhihong Fang1, Zhifeng Li1, Yiming Luo1 and Bing Xu1

1Department of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen, P.R. China

2Thoracic Department, People’s Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou, P.R. China

Correspondence to:

Yiming Luo, email: lym8709790@aliyun.com

Bing Xu, email: xubingzhangjian@126.com

Keywords: myelodysplastic syndrome, TET2 mutation, prognosis, meta-analysis

Received: December 14, 2016     Accepted: March 22, 2017     Published: April 18, 2017

ABSTRACT

Tet methylcytosine dioxygenase2 gene (TET2) is one of the most frequently mutated gene in myeloid neoplasm, but the prognostic role of TET2 aberrations in myelodysplastic syndromes (MDS) remains unclear. Therefore, we performed a meta-analysis. Fourteen eligible studies with 1983 patients were included in this meta-analysis. Among these, 2 studies evaluated the impact that the TET2 expression level had on the prognosis. The combined hazard ratios (HR) estimated for overall survival (OS) was 1.00 (95%CI: 0.74 to 1.37; p=0.989) when comparing those with TET2 mutations with those without. Among the patients treated with hypomethylating agents (HMAs) or hematopoietic stem cell transplantation (HSCT), the pooled HR for OS was 1.02 (95% CI: 0.77-1.35, p=0.89) and 1.54 (95%CI: 0.69 to 3.44; p=0.29), respectively. We also conducted an analysis of the response rate to HMAs, and the OR was 1.73 (95%CI: 1.11 to 2.70; p=0.016). Additionally, subgroup analyses showed the pooled HR for OS was 0.93(95%CI: 0.44 to 1.98; P=0.849) in WHO-classified CMML patients and 1.02(95%CI: 1.02 to 3.46; p=0.042) in studies evaluated TET2 expression level. The analysis suggested TET2 mutations had no significant prognostic value on MDS. However, the response rates to HMAs were significantly different between those with and without TET2 mutations, and the low expression level of TET2 gene was significantly associated with a poor OS in MDS patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17177